Colin Hislop

Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial

Jordan J. Feld, Christopher Kandel, Mia J. Biondi et al. · The Lancet Respiratory Medicine · 2021 · 237 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Early Treatment with Pegylated Interferon Lambda for Covid-19

Gilmar Reis, Eduardo A.S. Moreira Silva, Daniela C. Medeiros Silva et al. · New England Journal of Medicine · 2023 · 174 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +12

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study

Richard Furie, G. Léon, Meenu Thomas et al. · Annals of the Rheumatic Diseases · 2014 · 165 citations

Life Sciences, Immunology, Pharmacology +17

Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial

Prasanna Jagannathan, Jason R. Andrews, Hector Bonilla et al. · Nature Communications · 2021 · 147 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial

Robert S. Rosenson, Colin Hislop, Daniel McConnell et al. · The Lancet · 2009 · 114 citations

Medicine, Pharmacology, Biochemical Pharmacology +9